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Abstract
Background:  Angiotensin  converting  enzyme  inhibitors  are  effective  in  delaying  the  progression
of diabetic  retinopathy.  It  is  unknown  if  their  use  is  associated  with  a  better  visual  outcome  in
patients with  diabetic  macular  oedema.
Material  and  methods:  A  non-experimental,  comparative,  longitudinal  and  retrospective  study
was performed  on  patients  with  diabetic  macular  oedema  treated  by  focal  photocoagulation,
and with  systemic  arterial  hypertension  treated  with  angiotensin  converting  enzyme  inhibitors
(Group 1),  and  without  hypertension  (Group  2).  The  dependent  variable  was  the  proportion
with visual  improvement,  operatively  deﬁned  as  the  gain  of  one  or  more  lines  of  vision  three
weeks after  photocoagulation.  The  independent  variable  was  the  use  of  angiotensin  convert-
ing enzyme  inhibitors.  The  proportion  of  eyes  with  visual  improvement  after  treatment  was
compared between  groups  using  the  Chi  squared  (2)  test.
Results:  A  total  of  33  eyes  (51.6%)  were  assigned  to  group  1,  and  31  (48.2%),  to  group  2.
The mean  of  visual  acuity  improved  after  three  weeks,  compared  with  baseline  (p  =  0.002).
The proportion  of  eyes  with  visual  improvement  did  not  differ  between  patients  treated  with
angiotensin converting  enzyme  inhibitors  (45.5%)  and  those  that  did  not  use  them  (51.6%,
p =  0.4).
 Please cite this article as: Somilleda-Ventura SA, García-Rubio YZ, Razo Blanco-Hernández DM, Lima-Gómez V. Asociación entre la mejoría
visual y el uso de inhibidores de la enzima convertidora de angiotensina, en edema macular diabético. Cir Cir. 2016;84:269--274.
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Conclusions:  There  was  no  statistical  difference  in  the  proportion  of  eyes  with  visual  improve-
ment between  patients  treated  with  angiotensin  converting  enzyme  inhibitors  and  in  those
where they  were  not  used.  There  is  no  support  for  the  inhibition  of  angiotensin  II  in  addition  to
photocoagulation  for  improving  the  outcome  in  patients  with  diabetic  macular  oedema.
© 2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE
Oedema  macular
diabético;
Fotocoagulación
focal;
Inhibidores  de  la
enzima  convertidora
de  angiotensina;
Mejoría  visual;
Retinopatía  diabética
Asociación  entre  la  mejoría  visual  y  el  uso  de  inhibidores  de  la  enzima  convertidora
de  angiotensina,  en  edema  macular  diabético
Resumen
Antecedentes:  El  uso  de  inhibidores  de  la  enzima  convertidora  de  angiotensina  es  eﬁcaz  para
retardar la  progresión  de  retinopatía  diabética;  se  desconoce  si  su  empleo  se  asocia  con  un
mejor desenlace  visual  en  pacientes  con  oedema  macular  diabético.
Material  y  métodos: Estudio  observacional,  comparativo,  longitudinal  y  retrospectivo.  Se
evaluaron  pacientes  con  oedema  macular  diabético  tratados  mediante  fotocoagulación,  y
con hipertensión  arterial  sistémica  tratados  con  inhibidores  de  la  enzima  convertidora  de
angiotensina  (grupo  1),  y  no  hipertensos  (grupo  2).  La  variable  dependiente  fue  la  proporción
de mejoría  visual,  deﬁnida  operativamente  como  la  ganancia  de  una  o  más  líneas  de  visión,
3 semanas  después  de  la  fotocoagulación;  la  variable  independiente  fue  la  presencia  o  ausen-
cia del  tratamiento  con  inhibidores  de  la  enzima  convertidora  de  angiotensina.  Se  comparó  la
proporción  de  ojos  con  mejoría  visual  entre  grupos  mediante  2.
Resultados:  Treinta  y  tres  ojos  (51.6%)  se  asignaron  al  grupo  1  y  31  (48.4%)  al  2;  el  promedio
de agudeza  visual  mejoró  a  las  3  semanas,  con  respecto  al  basal  (p  =  0.002).  La  proporción  de
ojos con  mejoría  visual  no  diﬁrió  entre  los  pacientes  tratados  con  inhibidores  de  la  enzima
convertidora  de  angiotensina  (45.5%)  y  aquellos  que  no  los  recibían  (51.6%,  p  =  0.4).
Conclusiones:  La  proporción  de  ojos  con  mejoría  visual  entre  los  pacientes  tratados  con
inhibidores  de  la  enzima  convertidora  de  angiotensina  y  quienes  no  lo  usaban  no  tuvo  diferencia
signiﬁcativa.  No  se  sustenta  inhibir  la  angiotensina  II  como  terapia  adjunta  a  la  fotocoagulación
focal, para  mejorar  el  desenlace  en  pacientes  con  oedema  macular  diabético.
© 2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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tackground
acular  oedema  is  the  main  cause  of  sight  loss  in  patients
ith  any  degree  of  diabetic  retinopathy.  Macular  oedema  is
haracterised  by  thickening  of  the  macula  due  to  the  accu-
ulation  of  ﬂuid  in  the  retinal  tissue,  which  separates  the
hotoreceptors,  and  therefore  reduces  vision.1
The  loss  of  support  cells  in  the  capillaries  of  the  retina
pericytes)  forms  microaneurysms  and  enables  the  ﬁltration
f  liquid  and  inﬂammatory  elements  which  cause  macular
edema.2--4 Capillary  leakage  can  come  from  a  localised
esion  (focal  oedema),  or  from  an  extensively  damaged  net-
ork  of  capillaries  (diffuse  oedema).
The  standard  treatment  for  macular  oedema  with
ocalised  ﬁltration  is  focal  photocoagulation,  which  closes
he  sites  of  capillary  leakage  and  encourages  the  resorption
f  the  extravasated  ﬂuid.  This  treatment  reduces  the  inci-
ence  of  moderate  sight  loss  (3  lines  of  vision)  from  33%  to
3%.5Although  photocoagulation  achieves  involution  of
edema,  it  seldom  improves  vision.6,7 This  lack  of  improve-
ent  might  be  associated  with  other  elements  which
g
r
nontribute  towards  the  formation  of  thickening,  such  as
nﬂammation,  vascular  permeability  factors  and  angiotensin
I  (Ang  II).8
Vascular  endothelial  growth  factor,  also  known  as  the  vas-
ular  permeability  factor,  enables  the  transcytotic  transport
f  ﬂuid  towards  the  retina  via  structures  of  the  endothe-
ial  wall,  known  as  caveolae.  The  ﬂuid  that  leaks  through
he  caveolae  can  be  removed  using  the  ATPase  enzyme  of
he  pigment  epithelium.  This  mechanism  is  insufﬁcient  in
yes  with  macular  oedema,  due  to  the  increased  retinal
oncentration  of  vascular  endothelial  growth  factor,  which
ncourages  thickening  of  the  macula  to  persist.
Another  component  in  the  formation  of  diabetic  macu-
ar  oedema  is  the  rennin--angiotensin--aldosterone  system,
hich  also  exists  in  the  retina.9 Ang  II  is  a  hormone  which
egulates  the  balance  of  liquid  and  sodium,  and  cellular
rowth,10 and  exerts  its  effect  via  2  principal  receptors:
T1and  AT2.  The  AT1  receptors  mediate  vasoconstriction,
he  release  of  vasopressin  and  aldosterone,  ﬁbrosis,  cellular
rowth  and  migration.  The  AT2  receptors  involve  contra-
egulatory  reactions  such  as  vasodilation,  the  release  of
itric  oxide  and  inhibition  of  proliferation  and  growth.11
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sAssociation  between  visual  improvement  after  photocoagula
Synthesis  of  Ang  II  in  the  retina  takes  place  through
the  action  of  the  angiotensin  converting  enzyme,  which  is
produced  in  the  capillary  endothelium  and  in  the  retinal  pig-
ment  epithelium.  Ang  II  receptor  type  1  is  located  in  the
same  site  as  the  vascular  endothelial  growth  factor.12
It  has  been  reported  that  inhibitors  of  the  angiotensin
converting  enzyme  are  more  effective  in  reducing  the
incidence  and  progression  of  diabetic  retinopathy,  and  in
promoting  its  regression  in  type  2  diabetics.13 The  effect  of
blocking  Ang  II  in  a  short-term  event  has  not  been  described,
such  as  resolving  thickening  after  focal  photocoagulation,  in
eyes  with  diabetic  macular  oedema.
Ang  II  increases  the  expression  of  vascular  endothelial
growth  factor,  and  therefore  blocking  it  pharmacologically
would  theoretically  accelerate  the  resolution  of  macular
thickening,  by  reducing  the  capillary  ﬁltration  dependent  on
the  caveolae.  This  mechanism  might  facilitate  resolution  of
the  oedema  and  help  to  improve  visual  function  after  focal
photocoagulation.
A  study  was  undertaken  to  compare  the  proportion
of  eyes  with  visual  improvement  after  photocoagula-
tion,  between  patients  already  treated  with  angiotensin-
converting-enzyme  inhibitors  and  patients  who  had  not  been
treated  with  them,  in  order  to  establish  whether  blocking
Ang  II  might  be  effective  in  improving  the  functional  out-
come  in  diabetics  with  macular  oedema.
Material and methods
An  observational,  comparative,  longitudinal  and  retrospec-
tive  study  was  performed  on  patients  with  focal  diabetic
macular  oedema.
The  target  population  was  diabetic  patients  with  macular
oedema,  who  attended  the  Opthalmology  Department  of  the
Hospital  Juárez  de  México,  of  the  Secretaría  de  Salud  in  Mex-
ico  City  and  its  metropolitan  area.  The  accessible  population
comprised  patients  treated  in  a  general  hospital  between
26  March  2008  and  3  December  2013.  The  study  took  place
between  20  April  and  20  May  2015  and  was  authorised  by  the
Research  and  Ethics  Committee  and  Research  Committee  of
the  institution  where  it  was  carried  out.
Adult  patients  of  either  gender  were  included,  diagnosed
with  clinically  signiﬁcant  macular  oedema,  who  had  been
treated  using  focal  photocoagulation  by  the  same  retinal
consultant,  and  who  also  had  systemic  arterial  hyperten-
sion  treated  with  angiotensin-converting-enzyme  inhibitors
or  who  did  not  have  arterial  hypertension,  with  a  record
of  best-corrected  visual  acuity  under  subjective  refraction,
measured  in  decimal  equivalent,  with  a  rapid  macular  map
from  optical  coherence  tomography  on  the  date  of  the  pho-
tocoagulation  and  3  weeks  afterwards.
Patients  under  any  other  anti-hypertensive  treatment,  or
with  crystalline  opacity,  or  any  other  eye  diseases  which
reduced  vision  were  excluded  from  the  study.
Patients  who  did  not  attend  follow-up  visits  and  those
with  incomplete  data  were  removed  from  the  study.The  dependent  variable  was  improvement  of  visual  acu-
ity,  deﬁned  operationally  as  the  gain  of  one  or  more  lines  of
vision  after  photocoagulation.  The  independent  variable  was
the  use  of  angiotensin-converting-enzyme  inhibitors.  Both
c
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ominal  qualitative  variables  were  qualiﬁed  as  present  or
bsent.
Central  point  thickness,  central  ﬁeld  thickness  and  mac-
lar  volume  were  deﬁned  as  secondary  variables,  and
easured  by  optical  coherence  tomography  using  Stratus
CT  equipment  (Carl  Zeiss,  Meditec,  Dublin,  CA,  USA).  The
verages  of  change  were  measured  3  weeks  after  photoco-
gulation  using  the  Student’s  t-test  for  paired  samples.
The  proportion  of  eyes  with  visual  improvement  was
ompared  between  the  patients  treated  with  angiotensin-
onverting  enzyme  inhibitors  and  those  who  were  not,  using
he  2 test.
A  p  <  0.05  was  considered  signiﬁcant;  the  information  was
tored  and  analysed  using  SPSS  IBM  version  22,  for  Windows.
esults
ixty  four  eyes  of  53  patients  were  evaluated,  aged  between
5  and  80  (mean  61,  SD  ±  9.7);  35  were  male  (54.7%).  The
ourse  of  their  diabetes  was  from  one  to  30  years  (mean
4.4,  SDE  ±  6.9),  17  eyes  were  those  of  patients  treated  with
nsulin  (26.6%)  and  48  of  patients  treated  with  oral  hypogly-
aemics  or  diet.  Thirty-three  eyes  belonged  to  patients  with
ystemic  arterial  hypertension  (44.6%).
The  degree  of  diabetic  retinopathy  mild  non-proliferative
n  10  eyes  (15.6%),  moderate  non-proliferative  in  35  (54.7%),
evere  non-proliferative  in  3  (4.7%),  and  proliferative  in
6  (25%);  in  45  eyes  the  macular  oedema  was  monofocal
70.3%).
Before  photocoagulation,  the  visual  acuity  course  was
rom  0.13  to  1.00,  central  ﬁeld  thickness  from  146  to
87  m,  central  point  thickness  of  122--260  m,  and  the
acular  volume  from  6.24  to  8.76  mm3.  Three  weeks  after
hotocoagulation,  the  visual  acuity  course  was  from  0.10
o  1.00,  central  ﬁeld  thickness  from  131  to  313  m,  central
oint  thickness  from  112  to  307  m  and  macular  volume  from
.35  to  8.87  mm.3 The  comparison  of  the  variables  measured
n  the  day  that  the  selective  macular  laser  was  applied  and
 weeks  afterwards  is  shown  in  Table  1.
From  the  total  sample,  33  eyes  of  patients  treated
ith  angiotensin-converting-enzyme  inhibitors  (51.6%)  were
ssigned  to  group  1,  and  the  remaining  31  (48.4%)  to  group
.  The  comparison  of  variables  between  groups  is  shown  in
able  2;  there  were  no  differences  in  the  variables  between
he  two  groups  prior  to  treatment.
The  proportion  of  eyes  with  visual  improvement
f  patients  treated  with  angiotensin-converting-enzyme
nhibitors  (45.5%)  did  not  differ  signiﬁcantly  from  that  found
n  patients  who  were  not  receiving  this  treatment  (51.6%,
 =  0.40)  (Table  3).
iscussion
he  proportion  of  eyes  with  macular  oedema  showing  visual
mprovement  3  weeks  after  focal  photocoagulation,  was
imilar  between  the  patients  treated  with  angiotensin-
onverting-enzyme  inhibitors  and  those  who  were  not.
It  was  expected  that  the  proportion  of  eyes  with  visual
mprovement  after  photocoagulation  would  be  greater
n  patients  treated  with  angiotensin-converting-enzyme
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Table  1  Comparison  of  visual  acuity  and  anatomical  variables  on  the  day  of  treatment  and  3  weeks  afterwards.
Variables  Photocoagulationa p*
Day  of  treatment  Three  weeks  afterwards
Visual  acuity  0.5  ±  0.3  0.6  ±  0.3  0.002
CFT 172.8  ±  30.4  178.3  ±  37.2  0.04
CPT 206.9  ±  29.8  210.2  ±  32.2  0.10
Macular volume 7.6  ±  0.6 7.5  ±  0.6 0.03
CFT: central ﬁeld thickness; CPT: central point thickness.
a Mean ± SD.
* Student’s t-test for paired samples.
Table  2  Comparison  of  visual  acuity  and  anatomical  variables  between  groups.
Variables Treatment  with  ACEIa p
Yes  No
BCVA  0.5  ±  0.3  0.6  ±  0.3  0.70*
CPT  169  ±  33.2  176.8  ±  27.1  0.16*
CFT  201.8  ±  32  212.3  ±  26.6  0.31*
Macular  volume  7.6  ±  0.7  7.6  ±  0.6  0.88*
BCVA  <  20/40  18  (54.5%)  15  (48.4%)  0.40**
Central  thickening  9  (27.3%)  12  (38.7%)  0.24**
BCVA  3  weeks  afterwards  0.6  ±  0.3  0.6  ±  0.2  0.26*
CPT  3  weeks  afterwards  181.2  ±  47.8  175.2  ±  21.3  0.96*
CFT  3  weeks  afterwards  210  ±  39.7  210.5  ±  22.2  0.52*
Macular  volume  3  weeks  afterwards  7.5  ±  0.6  7.5  ±  0.6  0.91*
BCVA: best corrected visual acuity; CFT: central ﬁeld thickness; CPT: central point thickness.
a Mean ± SD.
* Student’s t test for independent samples.
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nhibitors,  due  to  the  beneﬁcial  effect  of  these  drugs  on
he  incidence  and  progression  of  diabetic  retinopathy.14
In  2007,  Cha  and  Kim15 reported  that  small  doses
f  angiotensin-converting-enzyme  inhibitors  showed  no
eneﬁcial  effects  in  delaying  the  progression  of  severe  non-
roliferative  diabetic  retinopathy.
In  2009,  Mauer  et  al.16 described  a  reduction  of  2  or
ore  stages  in  the  incidence  of  diabetic  retinopathy  pro-
ression  using  an  angiotensin-converting-enzyme  inhibitor
nd  an  Ang  II  receptor  1  blocker,  irrespective  of  changes
n  blood  pressure.  These  results  coincide  with  those  found
y  Harindhanavudhi  et  al.17 who  reported  in  2011  that  62  of
he  patients  treated  with  enalapril  and  losartan  (27.8%)  had
 signiﬁcant  reduction  of  65%  and  70%  in  the  incidence  of
iabetic  retinopathy  progression,  respectively.
b
e
p
Table  3  Comparison  of  visual  improvement  between  groups.
Treatment  with  ACEI  Visual  improvement  
Yes  15  (45.5%)  
No 16  (51.6%)  
ACEI: angiotensin-converting-enzyme inhibitors.
* 2.Hogeboom  van  Buggenum  et  al.18 found  in  2002  that
he  eyes  of  patients  treated  with  angiotensin-converting-
nzyme  inhibitors  had  lower  concentrations  of  vascular
ndothelial  growth  factor  in  the  vitreous,  compared  with
hose  of  patients  who  did  not  receive  this  treatment.  Reduc-
ng  the  ocular  concentration  of  vascular  endothelial  growth
actor  with  its  antagonist  drugs  is  the  principle  of  intrav-
treous  treatment  in  patients  with  macular  oedema.  The
ffect  of  Ang  II  was  theoretically  an  element  that  might  have
ncouraged  involution  of  the  thickening  and  visual  improve-
ent.
The  proportion  of  visual  improvement  did  not  changeetween  the  patients  treated  with  angiotensin-converting-
nzyme  inhibitors  and  those  who  were  not,  3  weeks  after
hotocoagulation.  This  might  be  because  the  intervention
No  visual  improvement  p*
18  (54.5%)  0.40
15  (48.4%)
tion
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on  Ang  II  might  have  had  less  of  an  effect  short  term.
Studies  evaluating  diabetic  retinopathy  progression  involve
long-term  measurements,  since  a  change  in  the  degree  of
retinopathy  is  not  expected  short  term.
Another  factor  which  might  have  intervened  is  that  the
Ang  II  blocker  might  have  inhibited  protective  functions,
such  as  those  regulated  by  the  Ang  II  type  2  receptor.  Pho-
tocoagulation  has  been  demonstrated  to  increase  the  gene
expression  of  Ang  II  type  2  receptors,19 which  promote  the
removal  of  intraretinal  ﬂuid.  Completely  blocking  the  pro-
duction  of  Ang  II  would  prevent  the  beneﬁcial  effects  of
activating  the  type  2  receptors,  and  those  associated  with
the  production  of  Ang  1--7.14
Angiotensin-converting-enzyme  inhibitor  2  turns  Ang  I
into  Ang  1--9  and  also  converts  Ang  II  into  angiotensin  1--7;
the  latter,  which  can  also  be  generated  from  Ang  1--9,  has  an
anti-proliferative  and  vasodilatory  action,  capable  of  coun-
teracting  the  effects  mediated  by  Ang  II  receptor  type  1
(Burrell  et  al.20 2004).  The  expression  of  1--7  reduces  as
diabetes  progresses;  Verma  et  al.  demonstrated  in  201214
that  injecting  recombinant  Ang  1--7  provides  a  protec-
tive  effect  against  the  incidence  of  diabetic  retinopathy  in
rodents.
It  has  been  described  that  angiotensin-converting-
enzyme  inhibitors  and  angiotensin  receptor  antagonists
(ARA  II)  do  not  cross  the  haemato-retinal  barrier,  due  to
their  molecular  weight.21 However,  in  clinically  signiﬁcant
macular  oedema,  damage  to  this  structure  enables  larger
molecules  (lipoproteins)  to  exit,22 which  would  allow  these
drugs  to  reach  the  retinal  tissue;  furthermore,  the  expected
effect  would  be  completed  in  the  endothelial  cells,23 and
therefore  it  would  not  be  essential  for  them  to  cross  the
haemato-retinal  barrier.
The  participation  of  the  renin--angiotensin  system  in  the
pathophysiology  of  diabetic  macular  oedema  has  already
been  documented,  but  the  site  has  not  yet  been  established
on  which  to  intervene  to  obtain  functional  improvement
with  adjunct  therapy.  Moreover,  from  the  available  biochem-
ical  information,  the  results  of  this  study  do  not  support  the
use  of  angiotensin-converting-enzyme  inhibitors  to  increase
the  incidence  of  visual  improvement  after  photocoagulation
in  diabetic  macular  oedema.  Therefore  the  use  of  Ang  II
receptor  1  antagonists  should  be  evaluated  prospectively  in
order  to  determine  whether  its  use  as  adjunct  therapy  after
photocoagulation  increases  the  incidence  of  visual  improve-
ment  in  diabetic  patients  with  macular  oedema.
Conclusions
The  proportion  of  eyes  with  visual  improvement  did  not
differ  signiﬁcantly  between  the  patients  treated  with
angiotensin-converting-enzyme  inhibitors  and  the  patients
who  were  not.  There  is  no  evidence  to  support  blocking  the
production  of  Ang  II  as  adjunct  therapy  after  focal  photoco-
agulation,  in  diabetic  macular  oedema.Conﬂict of interests
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